In the REFLEX (Randomized Evaluation of Long-Term Efficacy of Rituximab in RA) trial, Cohen and colleagues [9] evaluated primary efficacy and safety at 24 weeks in patients with active RA and an inadequate response to one or more anti-TNFα agents. The gene discussed is TNF; the disease is rheumatoid arthritis.